Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis

Trial Profile

A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Giant cell arteritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors IRIS; Servier
  • Most Recent Events

    • 19 Nov 2015 There is discrepancy in status among different countries as per EudraCT record (completed, recruiting and discontinued). Kept it as completed as maximum countries are showing the same though global end date is not provided.
    • 14 Nov 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
    • 10 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top